Black checkmark with a sparkle and a curved line underneath on a white background.
Company

HARVARD BIOSCIENCE INC

Ticker
HBIO
Sector
Industry
Report date
November 11, 2026
Valye AI Score

93

Very high visibility
Recent developments
Recent developments summary

Recent developments include quarterly earnings call transcripts for Q1, Q2, and Q3 2026, with reported revenue growth and updated growth outlooks. The company has undertaken strategic initiatives including manufacturing consolidation and leadership changes.

Recent developments:
  • Harvard Bioscience reported Q3 2026 earnings and discussed operational updates in its earnings call transcript [N1].
  • The company held a Q2 2026 earnings call where it reported an 11% rise in revenue and raised its FY26 growth outlook [N2][N3].
  • Q1 2026 earnings transcript provided insights into early-year performance and strategic initiatives [N4].
  • In mid-2025, John Duke was appointed CEO, with subsequent updates on revenue outlook and strategic direction [N8].
  • The company revealed Q3 2024 financial results highlighting ongoing operational performance [N5].
  • Steps have been taken to rationalize the product portfolio, reduce headcount in Europe and North America, and improve operating cost structure [S1].
Overview

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that support life science research, drug and therapy discovery, bioproduction, and preclinical testing. The company operates globally with customers including academic institutions, government laboratories, pharmaceutical and biotechnology companies, and contract research organizations. Its product portfolio is divided into two main families: Cellular and Molecular Technology (CMT), which supports molecular and cellular research and bioproduction, and Preclinical, which supports preclinical research and testing for drug development. The company also distributes third-party products to complement its offerings. Sales are conducted through direct and distributor channels worldwide. Strategic initiatives include Project Viking, a manufacturing consolidation plan to improve efficiency and reduce costs, and a focus on expanding higher-margin consumables and software revenue. Research and development efforts focus on maintaining and expanding the product portfolio to support growth and innovation [S1][S2].

Executive summary

Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Harvard Bioscience, Inc. is a global developer and manufacturer of life science research and preclinical testing products, organized into Cellular and Molecular Technology and Preclinical product families. The company serves pharmaceutical, biotechnology, academic, government, and CRO customers worldwide through direct and distributor sales. Strategic initiatives include Project Viking manufacturing consolidation and a focus on expanding consumables and software revenue. As of September 30, 2026, the company reported $4.856 million in cash, a current ratio of 1.76, and a net loss of $2.623 million for the quarter [S1][S2].

Scenarios for HBIO

Bull case model:

Harvard Bioscience's strategic focus on bridging in vivo and in vitro research through its Translational Bridge initiative positions it to address emerging markets such as organoid and 3D biology research. The introduction of innovative high-margin platforms like SoHo telemetry and proprietary MeshMEA and Incub8 systems supports modernization of preclinical workflows. Expansion of consumables and software revenue offers potential for increased recurring revenue and improved margins. Operational excellence initiatives, including Project Viking manufacturing consolidation and cost rationalization, aim to enhance profitability and cash generation. The company's diverse customer base and global sales channels provide a foundation for sustained business activity [S1][N3][N8].

Bear case model:

Risks include the company's net losses and negative earnings per share reported in recent quarters, indicating ongoing profitability challenges. The manufacturing consolidation under Project Viking involves restructuring charges and operational risks related to facility closures and transitions. Dependence on sole-source suppliers for some components may pose supply chain risks. Market competition in life science tools and services is intense, and shifts in customer demand or funding could impact revenues. The company's ability to successfully execute its strategic initiatives and maintain cost discipline will influence financial outcomes. Additionally, macroeconomic factors and regulatory changes could affect the business environment [S1][S2].

Moat:

Harvard Bioscience's moat is supported by its broad and complementary product portfolio spanning critical stages of life science research and preclinical testing, including proprietary technologies such as the MeshMEA system and SoHo telemetry platform. The company's established relationships with leading pharmaceutical, biotechnology, academic, and government customers globally, combined with its direct and distributor sales channels, provide market reach and customer diversification. Its manufacturing capabilities across multiple facilities and ongoing operational consolidation efforts contribute to cost efficiency. The company's focus on consumables and software expansion aims to increase recurring revenue streams, enhancing customer retention and revenue stability. These factors collectively contribute to a competitive position in the life sciences tools and services market [S1].

Risks overview
Risks summary
The primary risks center on the company's ongoing profitability challenges and the operational and financial risks associated with its manufacturing consolidation efforts under Project Viking.
Risks details:

• Profitability Challenges: The company reported a net loss of $2.623 million and negative EPS of -$0.58 for the quarter ended September 30, 2026, indicating ongoing challenges in achieving profitability [S2].
• Manufacturing Consolidation Risks: Project Viking involves closing the Holliston, MA manufacturing facility and transitioning production to other sites, which carries risks of operational disruption, restructuring charges estimated between $3.4 to $4.4 million, and potential asset write-offs [S1].
• Supply Chain Dependence: Some products depend on sole-source suppliers for key components, which may pose risks to manufacturing continuity and costs [S1].
• Market Competition and Demand: The life sciences tools and services market is competitive, and changes in customer funding or preferences could impact sales and revenue growth [S1].
• Execution and Cost Discipline: The company's ability to maintain operational efficiency, manage costs, and successfully implement strategic initiatives such as product portfolio rationalization and manufacturing consolidation will affect financial performance [S1].

FINAL FORECAST FOR HBIO

Final take one line
Harvard Bioscience exhibits high visibility through detailed disclosures of its life science product portfolio, strategic manufacturing consolidation, and recent financial results showing operational challenges and growth initiatives.
Final take 12 to 24 month view

Business trends: The company is focusing on bridging in vivo and in vitro research, expanding consumables and software revenue, and modernizing preclinical workflows with innovative platforms.
Execution milestones: Implementation of Project Viking manufacturing consolidation, product portfolio rationalization, and leadership under CEO John Duke.
Key risks: Profitability challenges, operational risks from manufacturing consolidation, supply chain dependencies, and competitive market pressures.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

93
LLM visibility overview
LLM Visibility known facts
  • Harvard Bioscience, Inc. is a Delaware corporation that develops, manufactures, and sells technologies, products, and services for life science applications including research, drug and therapy discovery, bioproduction, and preclinical testing for pharmaceutical and therapy development [S1].
  • The company operates globally with customers including academic institutions, government laboratories, pharmaceutical, biotechnology companies, and contract research organizations (CROs) [S1].
  • Harvard Bioscience's products are organized into two main product families: Cellular and Molecular Technology (CMT) and Preclinical [S1].
  • The CMT product family supports molecular, cellular, organ, and organoid research and bioproduction, including electroporation instruments, amino acid analyzers, spectrophotometers, precision pumps, electrophysiology instruments, and the MeshMEA system for organoid research [S1].
  • The Preclinical product family includes telemetry systems, behavioral products, isolated organ and surgical products, respiratory system solutions, inhalation and exposure systems, GLP-capable data acquisition and analysis systems, and the VivaMars behavioral monitoring system [S1].
  • Sales of CMT products accounted for approximately 46% of global revenues in 2025, while Preclinical products accounted for approximately 54% [S1].
  • The company also distributes third-party products, which accounted for about 13% of revenues in 2025 [S1].
  • Customers include major pharmaceutical and biotechnology companies such as Abbott, Amgen, AstraZeneca, Bayer, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, and Regeneron, as well as academic institutions like Harvard University and Stanford, and CROs such as Charles River Laboratories and Labcorp [S1].
  • Sales are conducted through a combination of direct sales and distributors, with approximately 61% of revenues from direct sales and 39% from distributors in 2025 [S1].
  • The company has a strategic plan called Project Viking to consolidate manufacturing operations by closing the Holliston, MA facility and shifting production to Minneapolis, MN and European sites, aiming for cost savings and operational efficiency [S1].
  • Research and development expenses were approximately $8.8 million in 2025, focused on maintaining and expanding the product portfolio [S1].
  • As of September 30, 2026, Harvard Bioscience reported cash and equivalents of $4.856 million, current assets of $45.977 million, current liabilities of $26.127 million, a current ratio of 1.76, and a cash ratio of 0.19 according to the latest 10-Q filing [S2].
  • The company reported a net loss of $2.623 million and basic and diluted EPS of -$0.58 for the quarter ended September 30, 2026 [S2].
  • Recent news includes quarterly earnings call transcripts for Q1, Q2, and Q3 2026, with Q2 revenue rising 11% and an updated FY26 growth outlook [N1][N2][N3][N4].
  • John Duke was appointed CEO in mid-2025, with subsequent updates on revenue outlook and strategic initiatives [N8].
  • The company has taken steps to rationalize its product portfolio, reduce headcount in Europe and North America, and improve operating cost structure [S1].
Sources
Sources - Context summary

Generated 2026-11-11

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-13 | 10-K
  • S2 | 2026-11-10 | 10-Q
Sources - News headlines
  • N1 | 2026-11-10 | www.nasdaq.com | Harvard Bioscience (HBIO) Q3 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/harvard-bioscience-hbio-q3-2026-earnings-call-transcript
  • N2 | 2026-08-18 | www.nasdaq.com | Harvard Bioscience (HBIO) Q2 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/harvard-bioscience-hbio-q2-2026-earnings-call-transcript
  • N3 | 2026-08-11 | www.nasdaq.com | Harvard Bioscience's Q2 Revenue Rises 11%; Raises FY26 Growth Outlook | https://www.nasdaq.com/articles/harvard-biosciences-q2-revenue-rises-11-raises-fy26-growth-outlook
  • N4 | 2026-05-12 | www.nasdaq.com | HBIO Q1 2026 Earnings Transcript | https://www.nasdaq.com/articles/hbio-q1-2026-earnings-transcript
  • N5 | 2026-03-14 | www.nasdaq.com | Harvard Bioscience Reveals Q3 2024 Financial Results | https://www.nasdaq.com/articles/harvard-bioscience-reveals-q3-2024-financial-results
  • N6 | 2026-03-12 | www.nasdaq.com | Harvard Bioscience (HBIO) Earnings Transcript | https://www.nasdaq.com/articles/harvard-bioscience-hbio-earnings-transcript
  • N7 | 2025-08-11 | www.nasdaq.com | Harvard Bioscience Tops Q2 Revenue Views | https://www.nasdaq.com/articles/harvard-bioscience-tops-q2-revenue-views
  • N8 | 2025-07-17 | www.nasdaq.com | Harvard Bioscience Appoints John Duke As Chief Executive Officer; Ups Q2 Revenue Outlook | https://www.nasdaq.com/articles/harvard-bioscience-appoints-john-duke-chief-executive-officer-ups-q2-revenue-outlook
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine